UroGen Pharma (URGN) Stock Forecast, Price & News

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for UroGen Pharma in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" URGN shares.
View URGN analyst ratings or view top-rated stocks.

2 analysts have issued twelve-month price objectives for UroGen Pharma's shares. Their URGN share price forecasts range from $10.00 to $23.00. On average, they anticipate the company's stock price to reach $16.50 in the next year. This suggests a possible upside of 49.2% from the stock's current price.
View analysts price targets for URGN or view top-rated stocks among Wall Street analysts.

UroGen Pharma's stock was trading at $8.87 on January 1st, 2023. Since then, URGN stock has increased by 24.7% and is now trading at $11.06.
View the best growth stocks for 2023 here.

UroGen Pharma saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 944,700 shares, an increase of 29.3% from the April 30th total of 730,500 shares. Based on an average daily volume of 175,400 shares, the days-to-cover ratio is presently 5.4 days. Currently, 4.8% of the company's shares are sold short.
View UroGen Pharma's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our URGN earnings forecast.

UroGen Pharma Ltd. (NASDAQ:URGN) announced its quarterly earnings data on Thursday, March, 16th. The company reported ($1.22) EPS for the quarter, missing analysts' consensus estimates of ($1.12) by $0.10. The business earned $18.09 million during the quarter, compared to analysts' expectations of $18.25 million.

ARK Israel Innovative Technology ETF holds 269,775 shares of URGN stock, representing 2.49% of its portfolio.

Based on aggregate information from My MarketBeat watchlists, some companies that other UroGen Pharma investors own include Sorrento Therapeutics (SRNE), Micron Technology (MU), OPKO Health (OPK), TG Therapeutics (TGTX), VBI Vaccines (VBIV), Exelixis (EXEL), (KITE) (KITE), Syndax Pharmaceuticals (SNDX), AbbVie (ABBV) and Aytu BioPharma (AYTU).

(URGN) raised $46 million in an initial public offering (IPO) on Thursday, May 4th 2017. The company issued 3,500,000 shares at a price of $12.00-$14.00 per share. Jefferies and Cowen and Company served as the underwriters for the IPO and Raymond James and Oppenheimer were co-managers.

UroGen Pharma trades on the NASDAQ under the ticker symbol "URGN."

UroGen Pharma's stock is owned by a number of institutional and retail investors. Top institutional investors include Stonepine Capital Management LLC (3.08%), BlackRock Inc. (1.25%), ARK Investment Management LLC (1.19%), Bank of America Corp DE (0.57%), State Street Corp (0.53%) and Meitav Investment House Ltd. (0.47%). Insiders that own company stock include Elizabeth A Barrett, Jason Drew Smith, Mark Schoenberg, Molly Henderson and Peter P Pfreundschuh.
View institutional ownership trends.

Shares of URGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of URGN stock can currently be purchased for approximately $11.06.

UroGen Pharma (NASDAQ:URGN) has a market capitalization of $251.50 million and generates $64.36 million in revenue each year. The company earns $-109,780,000.00 in net income (profit) each year or ($4.83) on an earnings per share basis.

The company employs 195 workers across the globe.

UroGen Pharma's mailing address is 400 Alexander Park, Princeton NJ, 08540. The official website for the company is www.urogen.com. The company can be reached via phone at (646) 768-9780 or via email at kate.bechtold@urogen.com.